TNF Pharmaceuticals Stock Price, News & Analysis

TNF Pharmaceuticals (NASDAQ: TNFA) has successfully closed a $7 million private placement of convertible preferred stock, priced at a significant 44% premium to market. The financing involves the sale of 7,000 preferred shares at $1,000 per share, convertible into 1.4 million common shares at $5.00 per share.

The placement includes warrants to purchase up to 1.4 million common shares at the same conversion price, subject to stockholder approval. The transaction was led by the company's largest strategic stockholder, with participation from existing investors. The funds will support the development of TNF's newly licensed light-based computing accelerator for blockchain technology, while the company continues developing isomyosamine and Supera-CBD assets.

PharmaCyte Biotech (Nasdaq:PMCB) has increased its investment in TNF Pharmaceuticals (Nasdaq:TNFA) by $3 million to support TNF's recent licensing agreement with LightSolver. The investment backs LightSolver's revolutionary processing accelerator technology, which uses light for computation to achieve 90% energy reduction while delivering superior performance compared to conventional computing methods.

The technology is planned for cryptocurrency mining and blockchain applications. TNF plans to change its name and ticker symbol to align with this new strategic direction. PharmaCyte maintains a strong financial position with total assets exceeding $55 million as of April 30, 2025, and continues to explore additional investment opportunities.

TNF Pharmaceuticals (Nasdaq: TNFA) has secured exclusive global rights to LightSolver's innovative laser-based processing unit (LPU) technology for cryptocurrency applications. The groundbreaking light-based computing system is designed to outperform quantum and supercomputing while reducing energy costs by up to 90%.

LightSolver, recognized as a 2025 World Economic Forum Technology Pioneer, has developed quantum-inspired LPU-based systems that operate at the speed of light. The company has also secured a $7 million private placement financing from strategic investors, with preferred stock convertible at $5.00 per share and accompanying five-year warrants.

TNF plans to rebrand to reflect its new strategic direction while continuing to evaluate options for its legacy therapeutic platforms.

TNF Pharmaceuticals (Nasdaq: TNFA), a clinical-stage biopharmaceutical company, has announced a 1-for-100 reverse stock split effective September 2, 2025. The split will reduce outstanding shares from 178,615,658 to 1,786,157.

The reverse split will maintain the stock's $0.001 par value, with fractional shares being rounded up. Proportional adjustments will be made to equity awards, convertible preferred stock, warrants, and other convertible securities. The company's new CUSIP number will be 62856X300.

This corporate action appears aimed at regaining Nasdaq listing compliance, with operational business updates expected to coincide with the split completion.

TNF Pharmaceuticals (NASDAQ:TNFA), a clinical-stage biopharmaceutical company, has announced a significant strengthening of its financial position. The company has achieved a substantial reduction in liabilities while maintaining total assets exceeding $17 million as of June 30, 2025.

The company is developing novel therapies for autoimmune and inflammatory conditions and maintains an ongoing collaboration with Renova focusing on GLP-induced inflammation and muscle damage. TNF's largest shareholder continues to provide strategic long-term support, positioning the company for future growth opportunities and shareholder value creation.

TNF Pharmaceuticals (Nasdaq: TNFA) has announced a philanthropic collaboration with the DADA2 Foundation to initiate a Compassionate Use study of their lead candidate isomyosamine for treating DADA2, a rare pediatric autoinflammatory disease.

DADA2 is characterized by systemic inflammation, vasculitis, early-onset stroke, and other severe complications, primarily affecting children. While biological TNF inhibitors are currently the only effective treatment, isomyosamine offers potential advantages as an orally administered small molecule TNF-alpha inhibitor with comparable potency and minimal immunosuppression.

The disease affects over 600 known patients, with research suggesting up to 35,000 undiagnosed cases globally. About 25% of patients are diagnosed before age one, and 77% by age ten.

TNF Pharmaceuticals (NASDAQ: TNFA) and Renova Health have announced positive results from their initial study analyzing 30,000 patients receiving GLP-1 agonists like Wegovy® or Ozempic®. The study aims to evaluate the potential of TNF's oral drug isomyosamine in preserving lean muscle mass during GLP-1 treatment for weight loss.

The research identified patient convergences between GLP-1 agonist use and inflammation-linked chronic disorders. Initial findings revealed that conditions like sarcopenia and frailty are underreported compared to CDC estimates, suggesting at-risk populations might experience adverse events from GLP-1 treatment without proper surveillance for muscle wasting. The data will be used to optimize patient recruitment and accelerate isomyosamine's development.

TNF Pharmaceuticals (NASDAQ: TNFA) and Renova Health have announced a collaboration leveraging AI and machine learning technologies to enhance drug development for muscle mass preservation during GLP-1 treatment. The partnership analyzes data from 30,000 patients to identify high-risk groups that could benefit from TNF's isomyosamine treatment.

The collaboration utilizes Renova's proprietary AI platform, featuring natural language processing (NLP) and large language models (LLM), to review patient records and identify optimal candidates. The target population includes patients with chronic conditions like diabetes, COPD, chronic kidney disease, or sarcopenia/frailty, who have experienced acute inflammatory events and are taking GLP-1 medications.

This AI-driven approach aims to optimize patient recruitment and accelerate TNF's drug development process, aligning with FDA's recent draft Guidance on AI usage in healthcare.

TNF Pharmaceuticals (NASDAQ: TNFA) presented clinical data for its oral TNF-alpha inhibitor, isomyosamine, at the British Geriatrics Society Spring Meeting 2025. The presentation, delivered by CMO Dr. Mitchell Glass, highlighted the drug's potential in treating sarcopenia in older adults.

Key findings from an earlier Phase 2 study demonstrated:

• Safety and tolerability in elderly patients with sarcopenia
• Significant reductions in inflammatory biomarkers including TNF-α, IL-6, and sTNFR1

The company is currently conducting a larger Phase 2b clinical trial focusing on cellular inflammation and recovery of ambulation speed in elderly patients post-hip fracture. The expanded trial features increased sample size and more frequent dosing to better evaluate clinical and biochemical outcomes. The company also plans to extend Phase 3 trials into the UK and Europe.